drugset / Trial / NCT05694936
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
Active not recruiting
38 enrolled
Australasian Gastro-Intestinal Trials Group
Olivia Newton-John Cancer Research Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.
Timeline
- Start
- 2023-01-23
- Primary completion
- 2026-01-21
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Valproate | Small molecule | 20 mg/kg | Oral |